(lidocaine hydrochloride) Ophthalmic Gel 3.5%
Akten™ (lidocaine hydrochloride ophthalmic gel) 3.5% is a sterile, preservative-free, single patient use ophthalmic gel preparation for topical ocular anesthesia. Lidocaine hydrochloride is designated chemically as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl) monohydrochloride with a molecular formula of C14H22N2O HCl and molecular weight of 270.8. The structural formula of the active ingredient is:
Akten™ contains 35 mg of lidocaine hydrochloride per mL as the active ingredient. Akten™ (lidocaine hydrochloride ophthalmic gel) also contains Hypromellose, Sodium Chloride, and Purified Water as inactive ingredients. The pH may be adjusted to 5.5 to 7.5 with Hydrochloric Acid and/or Sodium Hydroxide.
DOSAGE AND ADMINISTRATION
The recommended dose of Akten™ (lidocaine hydrochloride ophthalmic gel) is 2 drops applied to the ocular surface in the area of the planned procedure. Akten™ (lidocaine hydrochloride ophthalmic gel) may be reapplied to maintain anesthetic effect.
Dosage forms and Strength
Storage And Handling
Akten™ (lidocaine hydrochloride ophthalmic gel) 3.5% is supplied as a clear gel for single patient use as follows:
5mL fill in a 10mL natural, round plastic dropper bottle
Store at 15° to 25° C (59° to 77° F)
Keep container closed and protected from light in the original carton until use. Discard after use.
Manufactured by: Akorn Inc., Lake Forest, IL 60045. Rev. 09/08. FDA revision date: 10/7/2008
Included as part of the PRECAUTIONS section.
- Not for Injection.
- Corneal Opacification. Prolonged use of a topical ocular anesthetic may produce permanent corneal opacification and ulceration with accompanying visual loss.
Carcinogenesis, mutagenesis, Impairment of fertility
Long-term studies in animals have not been performed to evaluate the carcinogenic potential of Akten™ (lidocaine hydrochloride ophthalmic gel) .
Use In Specific Populations
Pregnancy. Pregnancy Category B.
Reproduction< studies for lidocaine have been performed in both rats and rabbits. There was no evidence of harm to the fetus at subcutaneous doses up to 50 mg/kg lidocaine (more than 800 fold greater than the human dose on a body weight basis) in the rat model. There are however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed.
Lidocaine is secreted in human milk. The clinical significance of this observation is unknown. Although no systemic exposure is expected with administration of Akten™ (lidocaine hydrochloride ophthalmic gel) , caution should be exercised when Akten™ (lidocaine hydrochloride ophthalmic gel) is administered to a nursing woman.
Safety and efficacy in pediatric patients has been extrapolated from studies in older subjects and studies in pediatric patients using different formulations of lidocaine.
No overall clinical differences in safety or effectiveness were observed between the elderly and other adult patients.
Prolonged use of a topical ocular anesthetic may produce permanent corneal opacification and ulceration with accompanying visual loss.
Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics or to unintended subarachnoid injection of local anesthetic solution. However, topical ocular application of Akten™ (lidocaine hydrochloride ophthalmic gel) is not expected to result in systemic exposure.
Mechanism Of Action
Akten™ (lidocaine hydrochloride ophthalmic gel) is a local anesthetic agent that stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Anesthesia generally occurs between 20 seconds to 1 minute and persists for 5 to 30 minutes.
Lidocaine may be absorbed following topical administration to mucous membranes. Its rate and extent of absorption depend upon various factors such as concentration, the specific site of application, viscosity of the agent, and duration of exposure.
The plasma binding of lidocaine is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentrations of 1 to 4 mcg of free base per mL, 60 to 80 percent of lidocaine is protein bound. Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein.
Lidocaine is metabolized rapidly by the liver, and metabolites and unchanged drug are excreted by the kidneys. Biotransformation includes oxidative Ndealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation. N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide. The pharmacologic/toxicologic actions of these metabolites are similar to, but less potent than, those of lidocaine. Approximately 90% of lidocaine administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged. The primary metabolite in urine is a conjugate of 4-hydroxy-2, 6-dimethylaniline.
Studies of lidocaine metabolism following intravenous bolus injections have shown that the elimination half-life of this agent is typically 1.5 to 2 hours. Because of the rate at which lidocaine is metabolized, any condition that affects liver function may alter lidocaine kinetics. The half-life may be prolonged twofold or more in patients with liver dysfunction. Renal dysfunction does not affect lidocaine kinetics but may increase the accumulation of metabolites.
A total of 209 subjects were enrolled, with 54, 51, 53, and 51 subjects randomized to the sham, Akten™ (lidocaine hydrochloride ophthalmic gel) 1.5%, Akten™ (lidocaine hydrochloride ophthalmic gel) 2.5%, and Akten™ (lidocaine hydrochloride ophthalmic gel) 3.5% groups, respectively. Ocular anesthesia was achieved within 5 minutes of anesthetic application by 47 of 51 subjects (92%) in the Akten™ (lidocaine hydrochloride ophthalmic gel) 3.5% group.
The mean time to anesthesia onset ranged from 20 seconds to 5 minutes was not affected by Akten™ (lidocaine hydrochloride ophthalmic gel) dose. The mean time to anesthesia onset was approximately 60 seconds, with a median onset time of 40 seconds for the Akten™ (lidocaine hydrochloride ophthalmic gel) 3.5% group. Among the subjects in the Akten™ (lidocaine hydrochloride ophthalmic gel) groups who achieved anesthesia within 5 minutes, approximately 90% had achieved anesthesia within 60 seconds of application.
The duration of anesthesia generally ranged from approximately 5 minutes to 30 minutes, with mean anesthesia durations of approximately 15 minutes for the Akten™ (lidocaine hydrochloride ophthalmic gel) 3.5% group.
Approximately 84% of the subjects in the Akten™ (lidocaine hydrochloride ophthalmic gel) 3.5% group experienced anesthesia for at least 5 minutes, approximately 55% of subjects experienced anesthesia for 10 minutes or longer and 27% experienced anesthesia for 15 minutes or longer. The anesthetic effect of additional applications of Akten™ (lidocaine hydrochloride ophthalmic gel) has not been evaluated.
No information provided. Please refer to the PRECAUTIONS section.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.